PUBLISHER: DelveInsight | PRODUCT CODE: 1705095
PUBLISHER: DelveInsight | PRODUCT CODE: 1705095
DelveInsight's "Liver Cirrhosis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Liver Cirrhosis, historical and forecasted epidemiology as well as the Liver Cirrhosis therapeutics market trends in the United States, EU4 and the UK (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
The Liver Cirrhosis market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Liver Cirrhosis market size from 2020 to 2034. The Report also covers current Liver Cirrhosis treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Liver Cirrhosis Treatment Market
Liver Cirrhosis Overview
Cirrhosis is the histological development of regenerative nodules surrounded by fibrous bands in response to chronic liver injury, leading to portal hypertension and end-stage liver disease. In this late-stage liver disease, the healthy liver tissue is replaced with scar tissue, and the liver is permanently damaged, and scar tissue keeps the liver from working properly. Cirrhosis has many signs and symptoms, such as fatigue and severe itchy skin, and they may not appear until the liver is badly damaged. Causes include alcoholic liver disease, nonalcoholic fatty liver disease, chronic hepatitis C, and chronic hepatitis B.
Liver Cirrhosis Diagnosis
Organizations like the European Association for the Study of the Liver (EASL), the Japanese Society of Gastroenterology (JSGE), and the American Association for the Study of Liver Diseases (AASLD), and others have published criteria for diagnosing liver cirrhosis.
Most people with early-stage liver cirrhosis do not exhibit any symptoms. Cirrhosis is frequently initially identified during a regular blood test or checkup. Laboratory and imaging tests are typically performed to help confirm a diagnosis. The key diagnosis that confirms cirrhosis is the biopsy, an invasive diagnostic procedure. Even though percutaneous liver biopsy (PLB) has very low mortality and morbidity rates, patients frequently find it uncomfortable and frightening.
When visible symptoms like jaundice start to show up, the disease progresses to the end stage, which is irreversible and cannot be cured, leaving liver transplantation as the last option. Before the onset of an irreversible disease, a diagnosis would allow for interventions (such as alcohol brief interventions, antiviral therapies, and weight loss). Hence, finding time to prioritize patients who are healthy but at-risk patients is difficult in a health system already trying to deliver good quality care to people with established diseases.
One of the major unmet needs in cirrhosis treatment is better methods to detect cirrhosis early before it progresses to a more severe stage. Improved screening and diagnostic tools, such as noninvasive tests and biomarkers, are needed to detect cirrhosis earlier. Also, there is a significant need for biomarkers to diagnose, monitor, and manage cirrhosis. Biomarkers are measurable indicators of a biological process, and they can be used to identify and track disease progression, predict treatment response, and monitor the effectiveness of therapy.
Biomarkers can be used to detect cirrhosis at an early stage before symptoms develop. They can also be used to monitor disease progression and response to treatment. This can help healthcare providers adjust treatment plans and improve patient outcomes. Biomarkers can be used in clinical trials to identify patients more likely to respond to a particular therapy which will eventually help drug developers design more effective treatments for cirrhosis.
Currently, the diagnosis and monitoring of cirrhosis rely mainly on imaging tests and blood tests that measure liver function. While these tests are helpful, they are not always accurate or sensitive enough to detect early-stage cirrhosis or predict disease progression. Therefore, developing more accurate and reliable biomarkers is critical for improving the diagnosis, monitoring, and management of cirrhosis.
Liver Cirrhosis Treatment
The treatment for cirrhosis depends on what has caused it. Cirrhosis cannot usually be cured, but there are ways to manage the symptoms and complications and stop the condition from worsening. Some of the diseases that cause cirrhosis can be cured. Treating the underlying causes of cirrhosis may keep cirrhosis from worsening and help prevent liver failure. Successful treatment may slowly improve some liver scarring.
Treating the underlying cause of liver damage - for example, treating underlying hepatitis (B or C) virus infection, or the removal of blood to lower iron levels in hemochromatosis
Making dietary and lifestyle changes - a nutritious, low-fat, high-protein diet and exercise can help people to avoid malnutrition.
Chronic liver disease patients, especially those with decompensated cirrhosis, often face several potentially life-altering consequences that can significantly affect daily activities and quality of life. They have specific needs for high levels of supportive care due to their disabilities and the complicated treatments that go along with them.
To provide the proper care, it is crucial to identify the underlying cause of hepatic decompensation through a thorough history, examination, and investigations. Cirrhosis can lead to a variety of complications, such as ascites (fluid accumulation in the abdomen), hepatic encephalopathy (brain dysfunction due to liver failure), and variceal bleeding (bleeding from enlarged veins in the esophagus or stomach). Although treatments are available for these complications, they are often ineffective and have significant side effects. Hemodialysis, IV antibiotics, and banding surgeries are all forms of treatment and are expensive. Better therapies are needed to manage these complications and improve the quality of life for patients with cirrhosis.
The most significant treatment for liver cirrhosis is a liver transplant, which is costly and burdens the patients and their families. It has been noticed that patients who require liver transplants are more than donors of the liver, making the treatment of cirrhosis patients a crucial task, and about 30% die waiting. Decompensated cirrhosis is frequent in acute care facilities and has a high fatality rate. A care bundle can help ensure that patients receive the right management of their difficulties systematically. The further development of new and novel treatments should take care of the significant burden on patient life by reducing the cost of therapies.
As the market is derived using the patient-based model, the Liver Cirrhosis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Liver Cirrhosis, and Etiology-specific Diagnosed Prevalent Cases of Liver Cirrhosis in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.
The drug chapter segment of the Liver Cirrhosis report encloses a detailed analysis of Liver Cirrhosis off-label drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Liver Cirrhosis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Liver Cirrhosis Emerging Drugs
Efruxifermin (AKR-001): Akero Therapeutics, Inc.
Efruxifermin (EFX), formerly AKR-001, is Akero's lead product candidate for MASH cirrhosis. EFX is designed to offer convenient once-weekly SC dosing. The consistency and magnitude of observed effects position EFX to be a potentially best-in-class medicine if approved. EFX is currently being evaluated in Phase IIb clinical trials in patients with biopsy-confirmed NASH: the SYMMETRY study in cirrhotic patients with compensated F4 fibrosis. EFX shows the potential to be an effective treatment for patients with cirrhosis due to MASH. Currently the drug is in Phase II of clinical development for the treatment of MASH cirrhosis.
Belapectin (GR-MD-02): Galectin Therapeutics Inc.
Belapectin (GR-MD-02), a galectin-3 inhibitor, has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent its complication: the development of esophageal varices. Belapectin can potentially treat many diseases due to galectin-3's involvement in multiple key biological pathways such as fibrosis, immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death). The importance of galectin-3 in the fibrotic process is supported by experimental evidence. Animals with the galectin-3 gene "knocked-out" can no longer develop fibrosis in response to experimental stimuli compared to animals with an intact galectin-3 gene. The company is using galectin-3 inhibitors to treat advanced liver fibrosis and liver cirrhosis in MASH patients. They have completed two Phase I clinical studies, a Phase II clinical study in MASH patients with advanced fibrosis (NASH-FX) and a second Phase IIb clinical trial in MASH patients with compensated cirrhosis and portal hypertension (NASH-CX).
Belapectin (GR-MD-02) is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that belapectin binds to galectin-1 and galectin-3, with greater binding affinity to galectin-3. Belapectin targets extracellular galectins.
A Phase II clinical trial of belapectin in NASH cirrhosis was the first large, randomized clinical trial of any drug to demonstrate a clinically meaningful improvement in portal hypertension or liver biopsy in patients with NASH cirrhosis without varices.
Zibotentan/dapagliflozin: Astrazeneca
AstraZeneca's combination therapy, zibotentan/dapagliflozin, is currently in Phase II clinical development targeting liver cirrhosis. This innovative treatment leverages the synergistic mechanisms of zibotentan, an endothelin A receptor antagonist, and dapagliflozin, a SGLT2 inhibitor marketed as Farxiga in the US and Forxiga globally. The small molecule duo is being evaluated in the ZEAL-UNLOCK study (Phase IIb) to assess its safety profile. Initiated in February 2024, this trial aims for a primary completion by January 2025. The study's impactful results could redefine therapeutic strategies for liver cirrhosis, addressing a significant unmet medical need.
With first approved therapy for advanced hepatic cirrhosis in 2024, the market outlook for liver cirrhosis is expected to expand.
The most popular drug classes used to treat Liver Cirrhosis include antivirals, antibiotics, antifibrotics, etc. For individuals with severely decompensated cirrhosis, early antiviral therapy is crucial. Antiviral therapy for Chronic Hepatitis B's primary objective is to reduce hepatic dysfunction and save patients from death. Interferon alpha (IFN) and nucleos (t) ide analogs are antiviral medications that are clinically used.
Currently there are no approved therapies for Liver Cirrhosis. Recently, in March 2024, Madrigal Pharmaceuticals' groundbreaking product, REZDIFFRA (resmetirom), a once-daily, oral THR-B agonist, received accelerated endorsement from the US FDA based on results from the Phase III MAESTRO-NASH trial. This approval marks a significant stride in the medical landscape, as REZDIFFRA becomes the inaugural and sole FDA-sanctioned therapy for adults afflicted with non-cirrhotic MASH, accompanied by moderate to advanced liver scarring (fibrosis) corresponding to stages F2-F3 fibrosis. Resmetirom (MGL-3196) is not approved for the treatment of liver cirrhosis.
The exclusion criteria for the Phase III clinical trial of resmetirom specifically excluded patients with cirrhosis, defined as stage 4 fibrosis. Additionally, the abstract of the MAESTRO-NAFLD-1 trial states that resmetirom was evaluated in adults with nonalcoholic fatty liver disease and presumed MASH, but does not mention cirrhosis.
The launch of emerging therapies, such as Belapectin/ GR-MD-02 (Galectin Therapeutics Inc.), Efruxifermin (Akero Therapeutics, Inc), Zibotentan/dapagliflozin (Astrazeneca), and others are expected to impact the market positively. The approval of these therapies could significantly impact market dynamics, although their success rates remain uncertain.
This section focuses on the uptake rate of potential drugs expected to launch in the market during 2020-2034. For example, Belapectin in the US is expected to be launched by 2026 with a peak share of 4.0%. Efruxifermin is anticipated to take 6 years to peak with a medium uptake.
Liver Cirrhosis Pipeline Development Activities
The report provides insights into different Liver Cirrhosis clincial trials within Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Liver Cirrhosis emerging therapies.
KOL Views
To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on Liver Cirrhosis evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including KOL from the University of Florida Gainesville, Stanford University, Liver Unit, Hospital Clinic of Barcelona, Iwate Medical University, Leipzig University Hospital, University of Florida Gainesville, Florida, Service des Maladies de l'Appareil digestif, Hopital Huriez, CHU, Lille, France, Liver Unit, Hospital Clinic of Barcelona, Barcelona, Spain, Division of Hepatology, Department of Internal Medicine, Iwate Medical University, Morioka, and others.
Delveinsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current and emerging therapies, treatment patterns, or Liver Cirrhosis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Qualitative Analysis
We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.
Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.
Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.
Market Access and Reimbursement
The high cost of therapies for the treatment is a major factor restraining the growth of the global drug market. Because of the high cost, the economic burden is increasing, leading the patient to escape from proper treatment.
The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.
Scope of the Liver Cirrhosis Market Report
Key Questions Answered In The Liver Cirrhosis Market Report:
Liver Cirrhosis Market Insights
Liver Cirrhosis Epidemiology Insights
Current Liver Cirrhosis Treatment Scenario, Marketed Drugs, and Emerging Therapies
Reasons to Buy Liver Cirrhosis Market Forecast Report
The Liver Cirrhosis Epidemiology and Market Insight report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of market dynamics and trends during this timeframe.
The Liver Cirrhosis market is quite robust. The major layers are Akero Therapeutics, Inc., Galectin Therapeutics Inc., and others which are currently developing drugs for the treatment of Liver Cirrhosis.
The market size is estimated through data analysis, statistical modeling, and expert opinions. It may consider factors such as incident cases, treatment costs, revenue generated, and market trends.
The increase in diagnosed prevalent cases of Liver Cirrhosis and the launch of emerging therapies are attributed to be the key drivers for increasing the Liver Cirrhosis market.
Introducing new therapies, advancements in diagnostic techniques, and innovations in treatment approaches can significantly impact the Liver Cirrhosis treatment market. Market forecast reports may provide analysis and predictions regarding the potential impact of these developments.
The market forecast report may include information on the competitive landscape, profiling key market players, their product offerings, partnerships, and strategies, and helping stakeholders understand the competitive dynamics of the Liver Cirrhosis marke